2017
Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53
Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D. Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53. Clinical Cancer Research 2017, 23: 5446-5459. PMID: 28630214, PMCID: PMC5600839, DOI: 10.1158/1078-0432.ccr-17-0342.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationCollagenDiagnostic ImagingDisease Models, AnimalDisease SusceptibilityExtracellular FluidFemaleGene Expression ProfilingHeterograftsHumansImmunohistochemistryMiceModels, BiologicalNeoplasm GradingNeoplasm InvasivenessRetrospective StudiesTumor Suppressor Protein p53ConceptsMammary glandBilateral mastectomy patientsInvasion scoreHigh-grade primary tumorsInterstitial fluidNormal mammary glandClin Cancer ResSporadic breast cancerBreast cancer cellsVisceral metastasesSpontaneous tumor formationClinical courseDuctal hyperplasiaResidual diseaseMastectomy patientsPrimary tumorDisease progressionRadiologic examinationBreast cancerLocal invasionMouse modelCollagen depositionMyofibroblast differentiationCancer ResExtracellular matrix
2009
Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm.
Germain D, Bahadur U, Halpern M, Adelson K, Raptis G, Waxman S, Ishii Y. Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm. Cancer Research 2009, 69: 5142-5142. DOI: 10.1158/0008-5472.sabcs-09-5142.Peer-Reviewed Original ResearchEfficacy of fulvestrantEstrogen receptorAromatase inhibitorsBreast cancer mouse modelPost-menopausal womenCancer mouse modelProteasome inhibitor bortezomibUnfolded protein responseEndometrial cancerPremenopausal womenFulvestrant resistanceStandard treatmentTamoxifen resistanceFulvestrant treatmentTumor regressionAgonist effectsClinical trialsBreast cancerMouse modelFulvestrantTherapeutic benefitConverts androgensAdipose tissueInhibitor bortezomibBortezomib